Court denies bid to halt Medicare drug price talks

Key Facts

• Chamber of Commerce to clarify whether AbbVie, the member company it cited in its lawsuit, actually manufactures Imbruvica, a cancer drug chosen for negotiation.
• Newman asked the Chamber, which challenged the program with state and local chambers of commerce, to amend its complaint to name which member companies of two of those groups would be affected by the program.
• He also asked the Chamber to clarify whether AbbVie, the member company it cited in its lawsuit, actually manufactures Imbruvica, a cancer drug chosen for negotiation.
• DOJ countered in legal filings that the Chamber and its members can’t show imminent harm from the program and asserted that the plaintiffs were speculating about who might be subject to negotiation, since the lawsuit was filed before CMS published its list on Aug. 29 of the first 10 drugs subject to negotiations.

Click To Read Full Article